Related Experiment Video
Updated: Mar 28, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in
A T Makadzange1,2, M Higgins-Biddle3, B Chimukangara2,4
1Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Insights
Delayed antiretroviral therapy (ART) initiation in children and adolescents with HIV negatively impacts immune recovery, growth, and virologic outcomes. Early ART initiation is crucial for better long-term health in pediatric HIV care.
Area of Science:
- Pediatric infectious diseases
- HIV/AIDS research
- Public health in low-income countries
Background:
- Routine HIV care programs in low-income countries face challenges in managing pediatric patients.
- Understanding outcomes for children and adolescents on antiretroviral therapy (ART) is critical for program improvement.
Purpose of the Study:
- To evaluate immunologic, virologic outcomes, and drug resistance in children and adolescents receiving HIV care.
- To assess the impact of age at ART initiation on health outcomes in a programmatic setting.
Main Methods:
- Cross-sectional study of 599 children and adolescents in a public ART program in Harare.
- Collection of clinical and laboratory data, including longitudinal records.
Main Results:
- Delayed ART initiation was associated with lower CD4 counts, severe stunting, and higher rates of virologic failure.
- Drug resistance was prevalent (67.6%); nevirapine-based regimens increased failure risk in children.
- Longer ART duration and earlier initiation in adolescence were linked to reduced virologic failure.
Conclusions:
- Delayed ART initiation in children and adolescents has significant long-term negative effects on immune recovery, growth, and virologic control.
- Optimizing ART initiation timing is essential for improving long-term outcomes in pediatric HIV care programs.
Objective:
To determine immunologic, virologic outcomes and drug resistance among children and adolescents receiving care during routine programmatic implementation in a low-income country.
Methods:
A cross-sectional evaluation with collection of clinical and laboratory data for children (0-<10 years) and adolescents (10-19 years) attending a public ART program in Harare providing care for pediatric patients since 2004, was conducted. Longitudinal data for each participant was obtained from the clinic based medical record.
Results:
Data from 599 children and adolescents was evaluated. The participants presented to care with low CD4 cell count and CD4%, median baseline CD4% was lower in adolescents compared with children (11.0% vs. 15.0%, p<0.0001). The median age at ART initiation was 8.0 years (IQR 3.0, 12.0); median time on ART was 2.9 years (IQR 1.7, 4.5). On ART, median CD4% improved for all age groups but remained below 25%. Older age (≥ 5 years) at ART initiation was associated with severe stunting (HAZ <-2: 53.3% vs. 28.4%, p<0.0001). Virologic failure rate was 30.6% and associated with age at ART initiation. In children, nevirapine based ART regimen was associated with a 3-fold increased risk of failure (AOR: 3.5; 95% CI: 1.3, 9.1, p = 0.0180). Children (<10 y) on ART for ≥4 years had higher failure rates than those on ART for <4 years (39.6% vs. 23.9%, p = 0.0239). In those initiating ART as adolescents, each additional year in age above 10 years at the time of ART initiation (AOR 0.4 95%CI: 0.1, 0.9, p = 0.0324), and each additional year on ART (AOR 0.4, 95%CI 0.2, 0.9, p = 0.0379) were associated with decreased risk of virologic failure. Drug resistance was evident in 67.6% of sequenced virus isolates.
Conclusions:
During routine programmatic implementation of HIV care for children and adolescents, delayed age at ART initiation has long-term implications on immunologic recovery, growth and virologic outcomes.
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics in Pediatric Patients: Drug Excretion
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Subviral Agents

